Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes

OBJECTIVE: To assess the efficacy and safety of MK-0941, a glucokinase activator (GKA), when added to stable-dose insulin glargine in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: In this double-blind study, 587 patients taking stable-dose insulin glargine (±metformin ≥1,500 mg/day) we...

Descripción completa

Detalles Bibliográficos
Autores principales: Meininger, Gary E., Scott, Russell, Alba, Maria, Shentu, Yue, Luo, Edmund, Amin, Himal, Davies, Michael J., Kaufman, Keith D., Goldstein, Barry J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220852/
https://www.ncbi.nlm.nih.gov/pubmed/21994424
http://dx.doi.org/10.2337/dc11-1200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220852/
https://www.ncbi.nlm.nih.gov/pubmed/21994424
http://dx.doi.org/10.2337/dc11-1200

Ejemplares similares